Key Points
- Director Gilbert Kliman sold 5,000 shares on Dec. 9 at an average price of $107.27 for a total of $536,350, reducing his stake by 12.53% to 34,905 shares (disclosed in an SEC Form 4).
- In the latest quarter Glaukos reported EPS of -$0.16 versus consensus -$0.27 and revenue of $133.54M (up 38.1%), beating both earnings and revenue estimates.
- Shares trade around $109 with a $6.28B market cap; analysts have a consensus rating of Moderate Buy and an average target of $120.62, and institutional investors own about 99.04% of the stock.
Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Gilbert Kliman sold 5,000 shares of the firm's stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total transaction of $536,350.00. Following the sale, the director owned 34,905 shares in the company, valued at approximately $3,744,259.35. This trade represents a 12.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Glaukos Stock Up 0.6%
Shares of NYSE:GKOS opened at $109.33 on Friday. The firm has a market capitalization of $6.28 billion, a PE ratio of -70.99 and a beta of 0.69. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $163.71. The firm has a fifty day moving average of $91.34 and a 200 day moving average of $92.70.
Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The business had revenue of $133.54 million for the quarter, compared to the consensus estimate of $122.55 million. During the same quarter last year, the business posted ($0.28) earnings per share. The company's revenue for the quarter was up 38.1% on a year-over-year basis. As a group, research analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently weighed in on the company. Stifel Nicolaus set a $115.00 target price on Glaukos in a research report on Monday, October 27th. UBS Group restated a "buy" rating and issued a $140.00 price objective on shares of Glaukos in a report on Monday, November 10th. Needham & Company LLC upped their price objective on shares of Glaukos from $117.00 to $125.00 and gave the company a "buy" rating in a research note on Tuesday. BTIG Research lifted their target price on shares of Glaukos from $104.00 to $116.00 and gave the stock a "buy" rating in a research report on Thursday, October 30th. Finally, Truist Financial set a $120.00 price target on shares of Glaukos in a research note on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $120.62.
Get Our Latest Report on GKOS
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. UMB Bank n.a. boosted its position in Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 158 shares during the period. Park Place Capital Corp increased its position in shares of Glaukos by 68.4% in the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier's stock valued at $41,000 after acquiring an additional 162 shares during the period. REAP Financial Group LLC bought a new position in shares of Glaukos during the third quarter valued at about $40,000. AlphaQuest LLC boosted its holdings in shares of Glaukos by 5,754.5% during the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier's stock worth $67,000 after purchasing an additional 633 shares during the period. Finally, Smartleaf Asset Management LLC grew its stake in shares of Glaukos by 16.2% in the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 136 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.
About Glaukos
(
Get Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
